IGF1R and Pleural effusion: The IGF1-R inhibitor linsitinib overcame osimertinib resistance in resistant cell lines and in the patient-derived KOLK43 cells [established from pleural effusion of a erlotinib- and osimertinib-resistant patient with high IGF1-R phosphorylation (36)].